20389-09-7

Basic information

• Product Name: 2-(2-CHLOROPHENYL)-4-QUINOLINECARBOXYLIC ACID
• Synonyms: BUTTPARK 153\33-44;2-(2-CHLOROPHENYL)-4-QUINOLINECARBOXYLIC ACID;2-(2-CHLORO-PHENYL)-QUINOLINE-4-CARBOXYLIC ACID;4-Carboxy-2-(2-chlorophenyl)quinoline;2-(2-chlorophenyl)cinchoninic acid
• CAS NO: 20389-09-7
• Molecular Formula: C₁₆H₁₀ClNO₂
• Molecular Weight: 283.71
• Product Categories: Quinoline&Isoquinoline
• Mol File: 20389-09-7.mol
• Article Data: 5

Chemical Properties

• Melting Point: 264-266
• Boiling Point: 464.6 °C at 760 mmHg
• Flash Point: 234.8 °C
• Appearance: /
• Density: 1.373 g/cm³
• Vapor Pressure: 1.97E-09mmHg at 25°C
• Refractive Index: 1.686
• PKA: 0.84±0.10(Predicted)
• CAS DataBase Reference: 2-(2-CHLOROPHENYL)-4-QUINOLINECARBOXYLIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(2-CHLOROPHENYL)-4-QUINOLINECARBOXYLIC ACID(20389-09-7)
• EPA Substance Registry System: 2-(2-CHLOROPHENYL)-4-QUINOLINECARBOXYLIC ACID(20389-09-7)

Safety Data

• Hazard Codes: Xi
• HazardClass: IRRITANT
• Hazardous Substances Data: 20389-09-7(Hazardous Substances Data)

Usage

General Description

2-(2-Chlorophenyl)-4-quinolinecarboxylic acid is a chemical compound with potential anti-inflammatory and antibacterial properties. It is a derivative of quinoline carboxylic acid and contains a chlorophenyl group, which may contribute to its pharmacological activities. 2-(2-CHLOROPHENYL)-4-QUINOLINECARBOXYLIC ACID has been studied for its potential use in treating conditions such as acne, dermatitis, and other inflammatory skin disorders. It may also have potential for use as an antibacterial agent, particularly against Gram-positive bacteria. Further research is needed to fully understand the therapeutic potential and mechanism of action of 2-(2-Chlorophenyl)-4-quinolinecarboxylic acid.

InChI:InChI=1/C16H10ClNO2/c17-13-7-3-1-6-11(13)15-9-12(16(19)20)10-5-2-4-8-14(10)18-15/h1-9H,(H,19,20)

Upstream product

• 2142-68-9 1-(2-chlorophenyl)ethanone 
• 484-38-8 isatic acid 
• 89-98-5 2-chloro-benzaldehyde 
• 127-17-3 2-oxo-propionic acid 
• 62-53-3 aniline 
• 91-56-5 indole-2,3-dione 
• 532-27-4 1-chloroacetophenone 

Downstream Products

• 107522-98-5 ethyl 2-(2-chlorophenyl)quinoline-4-carboxylate 
• 92566-67-1 2-(2-Chloro-phenyl)-quinoline-4-carbonyl chloride 

Relevant articles and documents

Synthesis of Novel Quinoline–Benzoxazolinone Ester Hybrids: In Vitro Anti-Inflammatory Activity and Antibacterial Activity

Abstract: A series of novel quinoline-benzoxazolinone ester hybrids were synthesized characterized and assessed for their in vitro anti-inflammatory and antibacterial activity. The in vitro anti-inflammatory activity was executed using protein denaturation assay, proteinase inhibitory assay and human red blood cell membrane stabilization assay. Most of the compounds exhibited potential anti-inflammatory activity. Compound (2-oxobenzo[d]oxazol-3(2H)-yl)methyl-2-(thiophen-2-yl)quinoline-4-carboxylate showed a better anti-inflammatory activity than the standard drugs diclofenac sodium and indomethacin. Furthermore, antibacterial activities of the synthesized compounds were evaluated using resazurin microtiter assay (REMA) and were compared with a positive drug standard chloramphenicol. The compounds demonstrated moderate to potent antibacterial activity. (2-Oxobenzo[d]oxazol-3(2H)-yl)methyl-2-(3,4-dimethoxyphenyl)quinoline-4-carboxylate and (2-oxobenzo[d]oxazol-3(2H)-yl)methyl-2-(2-chlorophenyl)quinoline-4-carboxylate displayed excellent activity against all bacterial strains in comparison to standard chloramphenicol. Moreover, cytotoxicity was performed on MDCK cells using MTT assay and it was found that none of the synthesized derivatives possessed any cytotoxicity.

Synthesis, Docking, ADME-Tox Study of 2-(2-(2-Chlorophenyl)quinoline-4-carbonyl)-N-substituted hydrazinecarbothioamide Derivatives and Their Biological Evaluation

A series of 2-(2-(2-chlorophenyl)quinoline-4-carbonyl)-N-substituted hydrazinecarbothioamide derivatives were synthesized by facile and efficient conventional method. The structures of the compounds were elucidated with the aid of an elemental analysis, I

Discovery of a novel class of selective non-peptide antagonists for the human neurokinin-3 receptor. 1. Identification of the 4-quinolinecarboxamide framework

A novel class of potent and selective non-peptide neurokinin-3 (NK-3) receptor antagonists, featuring the 4-quinolinecarboxamide framework, has been designed based upon chemically diverse NK-1 receptor antagonists. The novel compounds 33-76, prompted by chemical modifications of the prototype 4, have been characterized by binding analysis using a membrane preparation of chinese hamster ovary (CHO) cells expressing the human neurokinin-3 receptors (hNK-3-CHO), and clear structure-activity relationships (SARs) have been established. From SARs, (R)-N-[α-(methoxycarbonyl)benzyl]-2- phenylquinoline-4-carboxamide (65, SB 218795, hNK-3-CHO binding K(i) = 13 nM) emerged as one of the most potent compounds of this novel class. Selectivity studies versus the other neurokinin receptors (hNK-2-CHO and hNK-1-CHO) revealed that 65 is about 90-fold selective for hNK-3 versus hNK-2 receptors (hNK-2-CHO binding K(i) = 1221 nM) and over 7000-fold selective versus hNK-1 receptors (hNK-1-CHO binding K(i) = >100 μM). In vitro functional studies in rabbit isolated iris sphincter muscle preparation demonstrated that 65 is a competitive antagonist of the contractile response induced by the potent and selective NK-3 receptor agonist senktide with a K(b) = 43 nM. Overall, the data indicate that 65 is a potent and selective hNK-3 receptor antagonist and a useful lead for further chemical optimization.